Headquartered in New York City, New York, Wainscott Capital Partners is an opportunistic, actively-managed global long/short equity hedge fund that focuses primarily on biotech/healthcare investing. The fund employs a fundamentally driven, value-oriented approach to identify investment opportunities with the ability to offer annualized returns in the 20% – 30% range with a low correlation to the broader market.
Wainscott Capital Partners is a Delaware Limited Partnership. The fund’s fee structure involves a 2% management fee up to $200 million in total assets under management, and 1.5% thereafter. There is a 20% carry on profits above the high water mark. Fund investors are subject to a one-year lockup period. The minimum subscription amount is $500,000. Investment subscriptions are available on the first of each month.